Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal

Mutation-derived neoantigens are taking central stage as determinant in eliciting effective anti-tumor immune responses following adoptive T-cell therapies. These mutations are patient-specific and their targeting calls for highly personalized pipelines. The promising clinical outcomes of TIL therapy have spurred interest in generating T-cell infusion products that have been selectively enriched in neoantigen (or autologous tumor) reactivity....